Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA

* Participant is eligible to take part in the registry as per the product monograph. * Participants that are naïve to adalimumab therapy / or participants that have been receiving adalimumab therapy for less than 4 months. * Participant has moderately to severely active RA. * Participant who has had an inadequate response to one or more Disease Modifying Anti-Rheumatic Drugs (DMARDs). * Participant received provincial or private (insurance companies) approval for adalimumab. * Participant is able to give written informed consent and to understand the survey requirements.

* Participant to whom a traditional DMARD had never been tried. * Participant with a known hypersensitivity to adalimumab, or any of its components. * Participant is receiving free adalimumab as part of a compassionate program or an early access drug distribution program. * Participant with clinically significant concurrent medical or psychiatric disorders that may influence survey outcomes. * Participant with any condition that would prevent participation in the survey and completion of the survey procedures including language limitation or possibility that the participant will not be available for a period of time (\> 12 months) while being enrolled in the survey.